COVID-19 Therapeutics and Considerations for Pregnancy.

Joseph, Naima T; Collier, Ai-Ris Y

Joseph, Naima T; Collier, Ai-Ris Y.

Joseph NT; Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Kirstein 3rd Floor, Boston, MA 02215, USA; Department of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Boston, MA, USA. Electronic address: Njoseph5@bidmc.harvard.edu.
Collier AY; Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Kirstein 3rd Floor, Boston, MA 02215, USA; Department of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Boston, MA, USA.

Obstet Gynecol Clin North Am ; 50(1): 163-182, 2023 Mar.

Article in English | MEDLINE | ID: covidwho-2264976

ABSTRACT

ABSTRACT

The COVID-19 pandemic has generated an unprecedented amount of novel and repurposed vaccines and therapeutics that have been rapidly developed and implemented into clinical use. Unfortunately, pregnant persons have been excluded from most phase III clinical studies; therefore, our understanding regarding their safety for use in this population stems from understanding of theoretic risks and observational data. In this review, the authors discuss pregnancy-specific considerations for COVID-19 therapeutics.

Subject(s)

COVID-19; Female; Pregnancy; Humans; Pandemics

Keywords

COVID-19; Pregnancy; Therapeutics; Vaccines

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Female / Humans / Pregnancy Language: English Journal: Obstet Gynecol Clin North Am Journal subject: Gynecology / Obstetrics Year: 2023 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google